Loading…

Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells

We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D sub(3) [1,25(OH) sub(2)D sub(3)] inhibits adipogenesis in vitro. 1,25(OH) sub(2)D sub(3) blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24-48 h after th...

Full description

Saved in:
Bibliographic Details
Published in:American journal of physiology: endocrinology and metabolism 2006-05, Vol.290 (5), p.E916-E924
Main Authors: Kong, Juan, Li, Yan Chun
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page E924
container_issue 5
container_start_page E916
container_title American journal of physiology: endocrinology and metabolism
container_volume 290
creator Kong, Juan
Li, Yan Chun
description We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D sub(3) [1,25(OH) sub(2)D sub(3)] inhibits adipogenesis in vitro. 1,25(OH) sub(2)D sub(3) blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24-48 h after the differentiation is initiated, suggesting that 1,25(OH) sub(2)D sub(3) inhibits only the early events of the adipogenic program. Treatment of 3T3-L1 cells with 1,25(OH) sub(2)D sub(3) does not block the mitotic clonal expansion or C/EBP beta induction; rather, 1,25(OH) sub(2)D sub(3) blocks the expression of C/EBP alpha , peroxisome proliferator-activated receptor- gamma (PPAR gamma ), sterol regulatory element-binding protein-1, and other downstream adipocyte markers. The inhibition by 1,25(OH) sub(2)D sub(3) is reversible, since removal of 1,25(OH) sub(2)D sub(3) from the medium restores the adipogenic process with only a temporal delay. Interestingly, although the vitamin D receptor (VDR) protein is barely detectable in 3T3-L1 preadipocytes, its levels are dramatically increased during the early phase of adipogenesis, peaking at 4-8 h and subsiding afterward throughout the rest of the differentiation program; 1,25(OH) sub(2)D sub(3) treatment appears to stabilize the VDR protein levels. Consistently, adenovirus-mediated overexpression of human (h) VDR in 3T3-L1 cells completely blocks the adipogenic program, confirming that VDR is inhibitory. Inhibition of adipocyte differentiation by 1,25(OH) sub(2)D sub(3) is ameliorated by troglitazone, a specific PPAR gamma antagonist; conversely, hVDR partially suppresses the transacting activity of PPAR gamma but not of C/EBP beta or C/EBP alpha . Moreover, 1,25(OH) sub(2)D sub(3) markedly suppresses C/EBP alpha and PPAR gamma mRNA levels in mouse epididymal fat tissue culture. Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH) sub(2)D sub(3) occurs at the postclonal expansion stages and involves direct suppression of C/EBP alpha and PPAR gamma upregulation, antagonization of PPAR gamma activity, and stabilization of the inhibitory VDR protein.
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_20861974</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20861974</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_208619743</originalsourceid><addsrcrecordid>eNqNyssOwUAUgOGJkKjLO8xKSEwylw66dokFu-4Z7dAj0xl6WuHtkXgAq3_xfy0SCS0lE1rrNom4SBQTizjpkh7ilXM-17GMyHEfnM0aZypa2qwwHrCk4UzFVGqWQ_HKq_B8PaA2JXi6oticxmpCwRdwghqC_2KTwy1crLcI-FlUpYrtBM2sczggnbNxaIe_9slos06XW3arwr2xWB9KwK803oYGD5IvZiKZx-pv-AbmJEd4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20861974</pqid></control><display><type>article</type><title>Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells</title><source>American Physiological Society Free</source><creator>Kong, Juan ; Li, Yan Chun</creator><creatorcontrib>Kong, Juan ; Li, Yan Chun</creatorcontrib><description>We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D sub(3) [1,25(OH) sub(2)D sub(3)] inhibits adipogenesis in vitro. 1,25(OH) sub(2)D sub(3) blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24-48 h after the differentiation is initiated, suggesting that 1,25(OH) sub(2)D sub(3) inhibits only the early events of the adipogenic program. Treatment of 3T3-L1 cells with 1,25(OH) sub(2)D sub(3) does not block the mitotic clonal expansion or C/EBP beta induction; rather, 1,25(OH) sub(2)D sub(3) blocks the expression of C/EBP alpha , peroxisome proliferator-activated receptor- gamma (PPAR gamma ), sterol regulatory element-binding protein-1, and other downstream adipocyte markers. The inhibition by 1,25(OH) sub(2)D sub(3) is reversible, since removal of 1,25(OH) sub(2)D sub(3) from the medium restores the adipogenic process with only a temporal delay. Interestingly, although the vitamin D receptor (VDR) protein is barely detectable in 3T3-L1 preadipocytes, its levels are dramatically increased during the early phase of adipogenesis, peaking at 4-8 h and subsiding afterward throughout the rest of the differentiation program; 1,25(OH) sub(2)D sub(3) treatment appears to stabilize the VDR protein levels. Consistently, adenovirus-mediated overexpression of human (h) VDR in 3T3-L1 cells completely blocks the adipogenic program, confirming that VDR is inhibitory. Inhibition of adipocyte differentiation by 1,25(OH) sub(2)D sub(3) is ameliorated by troglitazone, a specific PPAR gamma antagonist; conversely, hVDR partially suppresses the transacting activity of PPAR gamma but not of C/EBP beta or C/EBP alpha . Moreover, 1,25(OH) sub(2)D sub(3) markedly suppresses C/EBP alpha and PPAR gamma mRNA levels in mouse epididymal fat tissue culture. Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH) sub(2)D sub(3) occurs at the postclonal expansion stages and involves direct suppression of C/EBP alpha and PPAR gamma upregulation, antagonization of PPAR gamma activity, and stabilization of the inhibitory VDR protein.</description><identifier>ISSN: 0193-1849</identifier><identifier>EISSN: 1522-1555</identifier><language>eng</language><ispartof>American journal of physiology: endocrinology and metabolism, 2006-05, Vol.290 (5), p.E916-E924</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids></links><search><creatorcontrib>Kong, Juan</creatorcontrib><creatorcontrib>Li, Yan Chun</creatorcontrib><title>Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells</title><title>American journal of physiology: endocrinology and metabolism</title><description>We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D sub(3) [1,25(OH) sub(2)D sub(3)] inhibits adipogenesis in vitro. 1,25(OH) sub(2)D sub(3) blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24-48 h after the differentiation is initiated, suggesting that 1,25(OH) sub(2)D sub(3) inhibits only the early events of the adipogenic program. Treatment of 3T3-L1 cells with 1,25(OH) sub(2)D sub(3) does not block the mitotic clonal expansion or C/EBP beta induction; rather, 1,25(OH) sub(2)D sub(3) blocks the expression of C/EBP alpha , peroxisome proliferator-activated receptor- gamma (PPAR gamma ), sterol regulatory element-binding protein-1, and other downstream adipocyte markers. The inhibition by 1,25(OH) sub(2)D sub(3) is reversible, since removal of 1,25(OH) sub(2)D sub(3) from the medium restores the adipogenic process with only a temporal delay. Interestingly, although the vitamin D receptor (VDR) protein is barely detectable in 3T3-L1 preadipocytes, its levels are dramatically increased during the early phase of adipogenesis, peaking at 4-8 h and subsiding afterward throughout the rest of the differentiation program; 1,25(OH) sub(2)D sub(3) treatment appears to stabilize the VDR protein levels. Consistently, adenovirus-mediated overexpression of human (h) VDR in 3T3-L1 cells completely blocks the adipogenic program, confirming that VDR is inhibitory. Inhibition of adipocyte differentiation by 1,25(OH) sub(2)D sub(3) is ameliorated by troglitazone, a specific PPAR gamma antagonist; conversely, hVDR partially suppresses the transacting activity of PPAR gamma but not of C/EBP beta or C/EBP alpha . Moreover, 1,25(OH) sub(2)D sub(3) markedly suppresses C/EBP alpha and PPAR gamma mRNA levels in mouse epididymal fat tissue culture. Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH) sub(2)D sub(3) occurs at the postclonal expansion stages and involves direct suppression of C/EBP alpha and PPAR gamma upregulation, antagonization of PPAR gamma activity, and stabilization of the inhibitory VDR protein.</description><issn>0193-1849</issn><issn>1522-1555</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNyssOwUAUgOGJkKjLO8xKSEwylw66dokFu-4Z7dAj0xl6WuHtkXgAq3_xfy0SCS0lE1rrNom4SBQTizjpkh7ilXM-17GMyHEfnM0aZypa2qwwHrCk4UzFVGqWQ_HKq_B8PaA2JXi6oticxmpCwRdwghqC_2KTwy1crLcI-FlUpYrtBM2sczggnbNxaIe_9slos06XW3arwr2xWB9KwK803oYGD5IvZiKZx-pv-AbmJEd4</recordid><startdate>20060501</startdate><enddate>20060501</enddate><creator>Kong, Juan</creator><creator>Li, Yan Chun</creator><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>20060501</creationdate><title>Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells</title><author>Kong, Juan ; Li, Yan Chun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_208619743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kong, Juan</creatorcontrib><creatorcontrib>Li, Yan Chun</creatorcontrib><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>American journal of physiology: endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kong, Juan</au><au>Li, Yan Chun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells</atitle><jtitle>American journal of physiology: endocrinology and metabolism</jtitle><date>2006-05-01</date><risdate>2006</risdate><volume>290</volume><issue>5</issue><spage>E916</spage><epage>E924</epage><pages>E916-E924</pages><issn>0193-1849</issn><eissn>1522-1555</eissn><abstract>We have investigated the molecular mechanism whereby 1,25-dihydroxyvitamin D sub(3) [1,25(OH) sub(2)D sub(3)] inhibits adipogenesis in vitro. 1,25(OH) sub(2)D sub(3) blocks 3T3-L1 cell differentiation into adipocytes in a dose-dependent manner; however, the inhibition is ineffective 24-48 h after the differentiation is initiated, suggesting that 1,25(OH) sub(2)D sub(3) inhibits only the early events of the adipogenic program. Treatment of 3T3-L1 cells with 1,25(OH) sub(2)D sub(3) does not block the mitotic clonal expansion or C/EBP beta induction; rather, 1,25(OH) sub(2)D sub(3) blocks the expression of C/EBP alpha , peroxisome proliferator-activated receptor- gamma (PPAR gamma ), sterol regulatory element-binding protein-1, and other downstream adipocyte markers. The inhibition by 1,25(OH) sub(2)D sub(3) is reversible, since removal of 1,25(OH) sub(2)D sub(3) from the medium restores the adipogenic process with only a temporal delay. Interestingly, although the vitamin D receptor (VDR) protein is barely detectable in 3T3-L1 preadipocytes, its levels are dramatically increased during the early phase of adipogenesis, peaking at 4-8 h and subsiding afterward throughout the rest of the differentiation program; 1,25(OH) sub(2)D sub(3) treatment appears to stabilize the VDR protein levels. Consistently, adenovirus-mediated overexpression of human (h) VDR in 3T3-L1 cells completely blocks the adipogenic program, confirming that VDR is inhibitory. Inhibition of adipocyte differentiation by 1,25(OH) sub(2)D sub(3) is ameliorated by troglitazone, a specific PPAR gamma antagonist; conversely, hVDR partially suppresses the transacting activity of PPAR gamma but not of C/EBP beta or C/EBP alpha . Moreover, 1,25(OH) sub(2)D sub(3) markedly suppresses C/EBP alpha and PPAR gamma mRNA levels in mouse epididymal fat tissue culture. Taken together, these data indicate that the blockade of 3T3-L1 cell differentiation by 1,25(OH) sub(2)D sub(3) occurs at the postclonal expansion stages and involves direct suppression of C/EBP alpha and PPAR gamma upregulation, antagonization of PPAR gamma activity, and stabilization of the inhibitory VDR protein.</abstract></addata></record>
fulltext fulltext
identifier ISSN: 0193-1849
ispartof American journal of physiology: endocrinology and metabolism, 2006-05, Vol.290 (5), p.E916-E924
issn 0193-1849
1522-1555
language eng
recordid cdi_proquest_miscellaneous_20861974
source American Physiological Society Free
title Molecular mechanism of 1,25-dihydroxyvitamin D sub(3) inhibition of adipogenesis in 3T3-L1 cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T12%3A56%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20mechanism%20of%201,25-dihydroxyvitamin%20D%20sub(3)%20inhibition%20of%20adipogenesis%20in%203T3-L1%20cells&rft.jtitle=American%20journal%20of%20physiology:%20endocrinology%20and%20metabolism&rft.au=Kong,%20Juan&rft.date=2006-05-01&rft.volume=290&rft.issue=5&rft.spage=E916&rft.epage=E924&rft.pages=E916-E924&rft.issn=0193-1849&rft.eissn=1522-1555&rft_id=info:doi/&rft_dat=%3Cproquest%3E20861974%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-proquest_miscellaneous_208619743%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=20861974&rft_id=info:pmid/&rfr_iscdi=true